Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $34.4 million.

  • Foghorn Therapeutics' Non-Current Assets fell 43.87% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 43.87%. This contributed to the annual value of $34.4 million for FY2024, which is 24.83% down from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Non-Current Assets is $34.4 million, which was down 24.83% from $45.7 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Non-Current Assets registered a high of $64.9 million during FY2020, and its lowest value of $34.4 million during FY2024.
  • In the last 3 years, Foghorn Therapeutics' Non-Current Assets had a median value of $45.7 million in 2023 and averaged $44.5 million.
  • Data for Foghorn Therapeutics' Non-Current Assets shows a maximum YoY declined of 24.83% (in 2024) over the last 5 years.
  • Foghorn Therapeutics' Non-Current Assets (Yearly) stood at $64.9 million in 2020, then dropped by 7.23% to $60.2 million in 2021, then fell by 11.17% to $53.5 million in 2022, then fell by 14.49% to $45.7 million in 2023, then dropped by 24.83% to $34.4 million in 2024.